Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 174,256,016
  • Shares Outstanding, K 2,374,060
  • Annual Sales, $ 49,436 M
  • Annual Income, $ 6,712 M
  • 36-Month Beta 0.77
  • Price/Sales 3.60
  • Price/Cash Flow 15.45
  • Price/Book 2.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.67 +2.67%
on 04/19/17
75.32 -0.94%
on 03/30/17
+0.24 (+0.32%)
since 03/24/17
3-Month
70.76 +5.44%
on 01/25/17
78.53 -4.99%
on 02/28/17
+4.58 (+6.54%)
since 01/24/17
52-Week
66.93 +11.47%
on 12/08/16
83.58 -10.73%
on 07/22/16
-1.87 (-2.45%)
since 04/22/16

Most Recent Stories

More News
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada

Novartis today announced an expanded commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine. This agreement builds on a 2015 global collaboration...

NVS : 74.61 (+1.65%)
AMGN : 163.14 (+1.70%)
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada

Novartis International AG / Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada . Processed and transmitted...

NVS : 74.61 (+1.65%)
Watch for Novartis to Potentially Pullback After Gaining 1.23% Yesterday

Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $74.06 to a high of $74.44. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $73.91 on...

NVS : 74.61 (+1.65%)
Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS

As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.

LLY : 83.42 (+1.87%)
NVS : 74.61 (+1.65%)
BIIB : 276.86 (+1.44%)
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*

Novartis International AG / Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe* . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible...

NVS : 74.61 (+1.65%)
What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?

GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.

CLDX : 3.22 (+0.62%)
NVS : 74.61 (+1.65%)
GILD : 66.25 (+0.49%)
GSK : 41.12 (+0.83%)
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

JNJ : 122.89 (+0.93%)
LLY : 83.42 (+1.87%)
AGN : 236.98 (+0.27%)
NVS : 74.61 (+1.65%)
RHHBY : 32.0100 (+1.30%)
SNY : 45.90 (+4.11%)
BMY : 53.55 (+0.13%)
Look for Shares of Novartis to Potentially Pullback after Yesterday's 1.18% Rise

Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $73.44 to a high of $73.91. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $73.52 on...

NVS : 74.61 (+1.65%)
Novartis Rises 1.18% on Heavy Volume: Watch For Potential Pullback

Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $73.44 to a high of $73.91. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $73.52 on...

NVS : 74.61 (+1.65%)
Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?

Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.

NVS : 74.61 (+1.65%)
GILD : 66.25 (+0.49%)
ICPT : 111.11 (+2.98%)
AMGN : 163.14 (+1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Support & Resistance

2nd Resistance Point 75.03
1st Resistance Point 74.82
Last Price 74.61
1st Support Level 74.23
2nd Support Level 73.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.